The GLP-1 Story Just Got a Second Act
Oral pills, Medicare coverage, and a triple-hormone drug showing bariatric-level weight loss. LLY is not done.
Oral pills, Medicare coverage, and a triple-hormone drug showing bariatric-level weight loss. LLY is not done.
Copper just hit record highs near $13,800 a tonne. The stocks mining it haven't fully caught up.
CRM is quietly becoming something different — and the market hasn't priced it in yet.
NATO rearmament, Middle East operations, and a record U.S. defense budget have defense names flying. The primes look crowded. The…
IonQ, Rigetti, and D-Wave are surging again – but insider behavior is flashing a signal the headlines aren't covering.
MU has surged over 200% YTD, Wolfe Research just raised its target to $1,250, and Q3 fiscal 2026 earnings drop…
The Claude maker confidentially filed its S-1 at a $965B valuation. The real story isn't Anthropic — it's what this…
AAPL slid while NVDA notched a stealth victory — and the divergence between their options flows tells the real story.
Three years of underperformance, a 20% valuation discount, and a mean-reversion case that's getting harder to ignore.
A $7 billion equity raise, $39 billion in AI server orders, and a stock in freefall — the setup is…